Tirzepatide Meets Both Primary End Points in Phase 3 SUMMIT Trial

SUMMIT (NCT04847557) is a multicenter, randomized, double-blind, parallel, placebo-controlled phase 3 trial that compared the efficacy and ...

SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide

The SUMMIT trial, the drug's manufacturer announced today, met statistical significance for both of its primary endpoints. Tirzepatide reduced a ...

Lilly's tirzepatide successful in phase 3 study showing benefit in ...

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure ...

Tirzepatide for Heart Failure with Preserved Ejection Fraction and ...

The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a ...

SUMMIT: Tirzepatide a 'Huge Win' for HFpEF Patients With Obesity

... two STEP-HFpEF trials wasn't due to chance. “With ... SUMMIT Meets Primary Endpoint for Safety, Efficacy of Tirzepatide: Topline Results.

SUMMIT Trial Proves Tirzepatide's Benefit in HFpEF with Obesity

Unlike these trials, the phase 3 SUMMIT trial included heart failure outcomes as a primary endpoint.1,2,3 ... Both variables had non-linear ...

Eli Lilly reports positive data from Phase III HFpEF treatment trial

In the trial, tirzepatide showed statistically significant improvements in both primary endpoints. ... tirzepatide in the SUMMIT trial was ...

Eli Lilly eyes tirzepatide cardio filings after late-stage win

In the phase 3 SUMMIT trial, Lilly's tirzepatide reduced the risk of ... In addition to the trial's two primary endpoints, tirzepatide met ...

Eli Lilly's Tirzepatide Shows Reduction in Risk of Heart Failure ...

Data emerged from the Phase III SUMMIT clinical trial, which met both of its primary endpoints as well as key secondary endpoints. 1.

Tirzepatide successful in phase III study showing benefit in adults ...

The study enrolled 731 patients with HF with preserved ejection fraction (HFpEF) and obesity. Besides meeting that primary endpoint of a ...

Tirzepatide demonstrated significant and superior weight loss ...

Tirzepatide met both co-primary endpoints demonstrating superiority ... The SURMOUNT phase 3 global clinical development program for tirzepatide ...

Updated: Eli Lilly's Zepbound reduces risk of heart failure outcomes ...

... Phase 3 study. Katherine Lewin. News Reporter. Eli ... Tirzepatide showed “statistically significant improvements” in both primary endpoints ...

Lilly's Tirzepatide Improves Heart Failure Outcomes

... met its two primary endpoints in the study and also met secondary endpoints. ... In the SUMMIT Phase III trial, injection with tirzepatide ...

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor ...

Based on the primary efficacy outcome from this study - that is, change in ... The phase III SUMMIT study (A study of tirzepatide (LY3298176) in ...

Lilly's tirzepatide successful in phase 3 study showing benefit in ...

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure ...

Continued Treatment With Tirzepatide for Maintenance of Weight ...

... primary end point at a 2-sided significance level of .05 using a 2 ... phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016 ...

Top-line data suggest improved outcomes, symptoms with ... - Healio

... phase 3 SUMMIT clinical trial. As Healio previously reported, the dual GLP-1/GIP agonist tirzepatide (Zepbound, Eli Lilly) was approved by ...

Tirzepatide Shows Statistically Significant Improvements in ...

Results from the SUMMIT Phase III clinical trial found that Eli Lilly's tirzepatide ... The primary objectives of the study were to reduce ...

Lilly's tirzepatide succeeds in phase 3 trial for heart failure with ...

... SUMMIT phase 3 clinical trial investigating the use of tirzepatide injections in adults. ... Key secondary endpoints were also met. These included ...

Tirzepatide Reduces Risk of Heart Failure Outcomes in Adults with ...

1 SUMMIT met all key secondary study endpoints, according to Lilly ... tirzepatide-successful-phase-3-study-showing-benefit 2. Halsey G ...